title: [Combination of cisplatin and vinorelbine as adjuvant chemotherapy in non-small cell lung cancer patients--feasibility assessment of 5 consecutively treated patients].
abstract: Post-operative adjuvant chemotherapy(POAC)combining cisplatin(CDDP)and vinorelbine(VNR)for non-small cell lung cancer(NSCLC)patients is considered as a standard regimen. However, some Japanese investigators point out the toxic profile of this regimen in the practice settings. Thus, five consecutive patients with mean age of 61.6 years old were treated to evaluate the feasibility of this regimen among Japanese patients. Three male and 2 female patients were enrolled, with post-operative stage of IIB/IIIA/IIIB in 1/2/2 patients, respectively. CDDP was administered on day 1 at 80 mg/m(2), and VNR on days 1 and 8 at 25 mg/m(2) intravenously, every 21 days. The regimen was aimed to complete 4 cycles, and 4 patients have completed the treatment without reducing the doses. Average treatment interval was 23 days. Four patients experienced grade(Gr)4 neutropenia, and 1 patient had Gr 3 liver damage. Other mild toxicities included Gr 1 nausea/vomiting in all patients, and Gr 1 GFR reduction in 3 patients. Combination of CDDP and VNR seems to be tolerable in terms of POAC, with relatively mild toxicity profile similar to the previous reports.
authors.affiliation: Division of Respiratory Medicine, Niigata University Medical and Dental Hospital.
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Hirahara
authors.forename: Junta
authors.initials: J
authors.lastname: Tanaka
authors.forename: Ryoh
authors.initials: R
authors.lastname: Itoh
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Kuriyama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tanaka
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kagamu
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Yoshizawa
authors.forename: Fumitake
authors.initials: F
authors.lastname: Gejyo
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine